Scientific principles demand that before newly developed alternative methods for safety testing are fully embraced by the industrial or regulatory community, they reliably and reproducibly predict the designated toxic end point. The process used to determine reliability and reproducibility is termed validation, and it generally culminates with a highly controlled, blinded study using multiple chemicals and laboratories. It is imperative that the validation study is designed to confirm the previously established reproducibility and predictive power of the assay. Much has been learned recently about the practical aspects of validation through investigation of alternative methods for acute toxicity testing, i.e., those methods that assess acute systemic toxicity, skin irritation, and eye irritation. Although considerable progress has been made-many alternative tests are now commonly used in various industrial settings-there have been few tests that have successfully passed a complete validation. Some of the barriers to successful validation have been a) lack of high-quality, reproducible animal data; b) insufficient knowledge of the fundamental biologic processes involved in acute toxicity; and c) the development of truly robust in vitro assays that can accurately respond to materials with a wide range of chemical and physical characteristics. It is recommended that to progress in the areas of eye and skin irritation we need to expand our knowledge of toxic markers in humans and the biochemical basis of irritation; progress in the area of acute systemic toxicity will require the development of in vitro models to determine gastrointestinal uptake, blood-brain barrier passage, and biotransformation.
Introduction
In applying scientific principles to the throughout the history of science by less problem of determining acceptability of structured but scientifically rigorous new, alternative methods for safety testing, approaches. This validation has been there is a need for a standard validation accomplished during the development of process. This validation process is described individual methodologies, publication of and referenced in this document. Scientific results in peer-reviewed journals, repetition methodologies have been validated of studies by independent laboratories, and acceptance by widespread use of the method. This less structured, but rigorous and scientifically acceptable approach will and should continue. However, it has become clear that more rapid progress will result if a more structured, formal approach to validation is adopted. This would include having a set of explicit criteria to use in the evaluation of any new method. As methods are reviewed for regulatory use, supportive data for compliance with how each method meets well-established criteria will provide a more rapid and effective review.
Use of Alternative Methods in Acute Toxicity Testing
Considerable research has been directed toward the development and validation of alternative methods for acute toxicity testing. Acute toxicity tests assess acute oral toxicity, skin irritation, and eye irritation. These tests are important for assessing chemical hazards due to a single shortterm exposure to a chemical. Historically, these assessments have been conducted in whole animals with the assumption that the results can be extrapolated to humans. For several important reasons discussed throughout this document, it would be useful to replace these animal-based tests with nonanimal alternative methods. A scheme for the inclusion of alternative methods in a typical safety assessment process is shown in Figure 1 . The first step in such processes usually includes a review of the historical data available on the chemical and an assessment of its physical-chemical properties. In many cases, quantitative structure-activity relationship (QSAR) models may be useful for such assessments. In some cases it is possible to characterize the chemical hazard based on these data alone. If more data are needed, the next step in the process is to conduct testing in some type of in vitro biological system. The new data are integrated with any other available information, and again, it is often possible to characterize the chemical hazard based on the total data package. If it is still not possible to complete the hazard assessment, the next step in the process is to determine if human data are needed. If so, it is necessary to consider whether the available information is sufficient to allow controlled human exposure. If 
Lessons Learned
Much attention has been given to the development and validation of alternative methods for acute toxicity testing in recent years. There are three reasons for this. The first is to improve the quality of the data obtained from acute toxicity tests. This is necessary for toxicologists to better predict and manage the risks associated with use of chemicals under defined conditions. Second, it is hoped that it is possible to develop methods that are less expensive and less time consuming. This will certainly be true for complex long-term studies such as 2-year bioassays. However, it is likely that alternative methods for other types of studies, such as some acute toxicity tests, will be more costly and may take more time. Finally, acute toxicity tests may be highly stressful to test animals. This has led to criticism of the procedures on ethical grounds. The development of nonanimal methods would allow toxicologists to obtain necessary information without the need for animals in the safety assessment process.
Numerous (Figure 2 ) and is based on information contained in reviews of validation prepared by international bodies such as the Organisation for Economic Co-operation and Development (OECD) (1) and from the scientific literature (2-4).
Definitions. Validation has been defined as the establishment of the reliability and relevance of an alternative method for a specific purpose (2) (3) (4) . Reliability refers to the demonstration of reproducibility of data obtained from a test method in the laboratory and the reproducibility of the predictions of toxic hazard following application of a clearly stated prediction model to the alternative method data (5) . Relevance refers to the establishment of scientific meaningfulness and usefulness of results from an alternative method for a particular purpose (2) (3) (4) Figure 2 . The validation process. The flow chart depicts the series of steps that may be used as a guide to design and conduct a validation program. The steps proceeding down the left side of the chart represent the validation process. The steps proceeding up the right side of the chart depict the steps associated with improving the performance of the alternative method and defining another prediction model prior to inclusion of the method in a subsequent validation study. Any new method, whether it is based on a fundamental understanding of toxic mechanisms or based on empirical correlations may be assessed for validity using this approach. From Bruner et al. (5) .
consider the method reliable. If the alternative method is not reliable, the validation process should end so that further method development may be undertaken (Figure 2) . If the optimization process is successful, the method may be evaluated in a subsequent study. Alternatively, the alternative method may be abandoned if additional work is unlikely to be fruitful. If the alternative method is reliable, the next step in the validation process is to assess its relevance (Figure 2 Once all of this information has been assembled and evaluated, the overall relevance of the method for its defined purpose must be assessed. If the conclusion is Environmental Health Perspectives * Vol 106, Supplement 2 * April 1998 that the alternative method is not relevant, the test cannot be considered valid and it is necessary to consider whether there is value in optimizing the assay, developing a new prediction model, and assessing it in a subsequent validation study (Figure 2) (1) . Conversely, if the data support its relevance, then it would suggest the alternative method can be used in the safety assessment process and should be considered for official acceptance by regulatory authorities (Figure 2) Historical animal and human data, QSAR, and physical/chemical assays can provide excellent data for initial evaluation and an appropriate road map to identify necessary studies. In some cases, if sufficient data exists, the material can be evaluated without further testing. In other cases it may be possible to directly use these materials in human testing.
A number of in vitro biological methods are currently being used and/or evaluated for their usefulness. These indude cell culture, reconstituted tissue equivalent (RTE), and skin explants.
For irritation a number of biological end points are used as a measure of cellular toxicity. Specific biochemical markers interleukin-1 (ILl), arachidonic acid, and the prostaglandins provide information on this inflammatory process. Histopathology and noninvasive techniques (e.g., transepidermal water loss, CO2 transport) are being evaluated mainly in RTE and in skin explants.
A potential strategy for irritation can be evaluated by using the general scheme in Figure 2. Step 1 includes physical and chemical properties, literature review, QSAR, historical data, and physical/ chemical assays.
Once the data are integrated and evaluated, then in vitro methods can be used (step 4). These could include cytotoxicity (e.g., Environmental Health Perspectives * Vol 106, Supplement 2 * April 1998 MTT reduction end point), biochemical measures, and histopathology. After further integration and evaluation of all data, it will be possible, in many cases, to go directly to human testing (step 9).
Corrosive testing, the extreme case of irritation, may be evaluated completely in step 1 as described above. In other cases histopathology, biochemical, or Corrositex testing may be required. If a known or suspected corrosive material is being evaluated for degree of severity, animal or human testing is inappropriate.
For allergic contact dermatitis (ACD) an understanding of the biological basis will provide appropriate mechanistic tests (10) . Specific approaches are currently under evaluation and one anticipates rapid understanding and significant methodology development. The biology of ACD suggests that specific cytokines (and/or their messenger RNA), adhesion molecules, and histochemistry will provide appropriate batteries of tests.
The biological systems most likely to be used include keratinocyte cell cultures, dendrite cell model (Langerhan cells and/or blood monocytes), and RTE. The results of ongoing QSAR studies are most encouraging. In fact, one might anticipate that QSAR and a single or limited battery of in vitro tests will provide sufficient data to identify and manage the risk of skin contact allergens.
A potential strategy for ACD using the general scheme in Figure 1 
